A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

Primary Sponsor

NCIC Clinical Trials Group (NCIC CTG)

Related Post

29 July, 2026

TROG to run breast cancer trial in Australia after gaining $2.86m grant

LATEST NEWS: 29 July 2026 TROG Cancer Research is

new TROG Scientific Committee Chair Elect and members
21 July, 2026

New TROG Scientific Committee Chair-Elect and members bring diverse experience

LATEST NEWS: 21 July 2026 The TROG Scientific Committee